These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23680861)

  • 1. Defibrotide: properties and clinical use of an old/new drug.
    Pescador R; Capuzzi L; Mantovani M; Fulgenzi A; Ferrero ME
    Vascul Pharmacol; 2013; 59(1-2):1-10. PubMed ID: 23680861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.
    Echart CL; Graziadio B; Somaini S; Ferro LI; Richardson PG; Fareed J; Iacobelli M
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):627-34. PubMed ID: 19809307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated view of the activities of defibrotide.
    Pescador R; Porta R; Ferro L
    Semin Thromb Hemost; 1996; 22 Suppl 1():71-5. PubMed ID: 8807733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolytic effects of defibrotide in atherosclerotic patients.
    Patrassi GM; Sartori MT; Viero ML; Scapinello MP; Boeri G; Girolami A
    Semin Thromb Hemost; 1991; 17 Suppl 1():101-5. PubMed ID: 2068562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.
    Ulutin ON; Cizmeci G; Balkuv-Ulutin S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):177-80. PubMed ID: 2459016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible role of defibrotide in endothelial cell protection.
    Corsi M; Parise M; Gaja G; Ferrero ME
    Int J Tissue React; 1993; 15(4):157-61. PubMed ID: 8188455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.
    Palmer KJ; Goa KL
    Drugs; 1993 Feb; 45(2):259-94. PubMed ID: 7681375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late-onset hepatic veno-occlusive disease post autologous peripheral stem cell transplantation successfully treated with oral defibrotide.
    Shah MS; Jeevangi NK; Joshi A; Khattry N
    J Cancer Res Ther; 2009; 5(4):312-4. PubMed ID: 20160371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Defibrotide].
    Gava R
    G Clin Med; 1988 Mar; 69(3):229-31. PubMed ID: 3169453
    [No Abstract]   [Full Text] [Related]  

  • 10. Deficient fibrinolytic response in patients with Raynaud's phenomenon and its correction with defibrotide.
    Cimminiello C; Milani M; Pietra A; Rossi F; Aloisio M; Nazzari M; Bonfardeci G
    Semin Thromb Hemost; 1991; 17 Suppl 1():106-11. PubMed ID: 2068563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Defibrotide: a new antithrombotic agent].
    Bán A
    Orv Hetil; 2001 Jun; 142(22):1193-4. PubMed ID: 11424595
    [No Abstract]   [Full Text] [Related]  

  • 12. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Corbacioglu S; Kernan N; Lehmann L; Brochstein J; Revta C; Grupp S; Martin P; Richardson PG
    Expert Rev Hematol; 2012 Jun; 5(3):291-302. PubMed ID: 22780209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defibrotide therapy for thrombophlebitis--controlled clinical trial.
    Di Perri T; Vittoria A; Messa GL; Cappelli R
    Haemostasis; 1986; 16 Suppl 1():42-7. PubMed ID: 3754835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the use of defibrotide.
    Guglielmelli T; Bringhen S; Palumbo A
    Expert Opin Biol Ther; 2012 Mar; 12(3):353-61. PubMed ID: 22283742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defibrotide is antithrombotic and thrombolytic against rabbit venous thrombosis.
    Niada R; Pescador R; Porta R; Mantovani M; Prino G
    Haemostasis; 1986; 16 Suppl 1():3-8. PubMed ID: 3519381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation.
    Abecasis MM; Conceição Silva JP; Ferreira I; Guimarães A; Machado A
    Bone Marrow Transplant; 1999 Apr; 23(8):843-6. PubMed ID: 10231151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defibrotide: an overview of clinical pharmacology and early clinical studies.
    Cornelli U; Nazzari M
    Semin Thromb Hemost; 1988; 14 Suppl():64-70. PubMed ID: 3057638
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical effectiveness of defibrotide in vaso-occlusive disorders and its mode of actions.
    Ulutin ON
    Semin Thromb Hemost; 1988; 14 Suppl():58-63. PubMed ID: 2848323
    [No Abstract]   [Full Text] [Related]  

  • 19. Proceedings of the defibrotide symposium. 8th International Congress on Thrombosis. Istanbul, June 4-7, 1984.
    Haemostasis; 1986; 16 Suppl 1():1-68. PubMed ID: 3754832
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostacyclin release from endothelial cells, induced by defibrotide treatment, favours the function of grafted rat hearts and kidneys.
    Ferrero ME; Marni A; Salari PC; Spaggiari PG; Gaja G
    Int J Tissue React; 1991; 13(4):215-8. PubMed ID: 1821415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.